Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AbbVie Inc.
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.
Currently available catheter-based devices for left-atrial appendage closure block the opening from the left atrium into the appendage, while Laminar’s innovative approach uses rotational motion to “eliminate” the LAA.
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
- Other Names / Subsidiaries
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.